UCB To Buy Ra for $2.1bn And Plays Down Antitrust Fears
Getting hold of zilucoplan, a 'pipeline in a product'
The deal, welcomed by analysts, means that the Belgian drug maker has two late-stage products for the rare disease myasthenia gravis to challenge Alexion's Soliris.
